Image source: The Motley Fool.

DATE

Monday, Sept. 14, 2026, at 5 p.m. ET

CALL PARTICIPANTS

• President and Chief Executive Officer-Jennifer Bath

TAKEAWAYS

• Revenue -- $3.8 million, representing a 21% increase driven by five consecutive quarters of year-over-year growth.
• Gross Margin -- 58.6%, expanding from 48.3% as revenue grew on a cost of sales that remained stable at $1.6 million.
• Gross Profit -- $2.2 million, an increase of 47% compared to $1.5 million in the prior-year quarter.
• Sales and Marketing Expense -- $3.2 million, an increase of $1.9 million reflecting planned investments in commercial infrastructure for the ReefIQ launch.
• Net Loss from Continuing Operations -- $6.1 million, compared to $4.1 million due to deliberate investments in enterprise adoption initiatives.
• Net Loss Per Share -- $0.13, compared to $0.09 for the same quarter in the previous year.
• Unsecured Revolving Credit Facility -- US$30 million, established with a fixed 7% rate and no financial maintenance covenants to provide liquidity without equity dilution.
• Cash Balance -- $7.6 million as of July 31, 2026, compared to $11.3 million at the end of the previous fiscal year.
• Net Cash Used in Operating Activities -- $4.0 million, a 4% decrease from $4.2 million.
• Commercial Funnel Structure -- 80%, representing the portion of the funnel by value now structured as platform partnerships rather than discrete projects.
• Active Clinical Trials -- 10 programs, spanning Phase I to Phase III development and including four first-in-class molecules.
• Client Portfolio -- 19 of the top 20 global pharmaceutical companies, which provides a distribution advantage for the adoption of ReefIQ.
• Research and Development Expense -- $1.3 million, up from $1.0 million, due to increased salary costs to support platform commercialization.
• General and Administrative Expense -- $3.9 million, an increase from $3.3 million, primarily driven by non-cash stock-based compensation.
• Total Operating Expenses -- $8.4 million, up 47% to support the commercial rollout of ReefIQ and LensAI.
• Adjusted EBITDA from Continuing Operations -- negative $5.1 million, compared to negative $3.7 million in the prior-year quarter.
• Accounts Receivable -- $2.0 million, forming part of the $12.2 million in total current assets.
• Unbilled Revenue -- $851,000, as of July 31, 2026, compared to $581,000 as of April 30, 2026.
• Total Liabilities -- $10.4 million, including $5.4 million in accounts payable and accrued liabilities.
• Lease Obligations -- $3.5 million, comprised of $483,000 in current liabilities and $3.0 million in long-term lease commitments.

Need a quote from a Motley Fool analyst? Email [email protected]

RISKS

• Richard Areglado warned that revenue from initial ReefIQ agreements is expected to be lumpy due to their milestone-based structure, which makes them difficult to forecast.
• Jennifer Bath stated, "Timelines there are hard to forecast," referring to the company's internal preclinical development pipeline and the parallel advancement of multiple programs.

SUMMARY

MindWalk Holdings Corp. (HYFT -13.91%) reported a 21% increase in revenue for the first quarter of fiscal 2027, driven by its transition toward a recurring revenue model following the June launch of the ReefIQ data platform. Management announced a binding commitment for a US$30 million unsecured credit facility at a fixed 7% interest rate, intended to fund enterprise onboarding and platform partnerships without shareholder dilution. The company is currently engaged in multiple negotiations with large pharmaceutical firms for enterprise-level deployments, shifting away from discrete project-based work to milestone and royalty-based economic structures. Approximately 80% of the current commercial funnel by value is now structured under these platform partnership agreements.

• The company validated a production deployment of OpenFold3 on AMD Instinct MI325X GPUs in collaboration with engineering partners AMD and Vultr.
• CEO Bath described ReefIQ as "the substrate layer between complex, unstructured biological data and AI models" that turns data into structured representations.
• Management noted that LensAI is "deliberately model neutral," allowing pharmaceutical clients to reason over biological data using proprietary, open-source, or third-party models.
• The gating factors for ReefIQ adoption include IT security and data governance reviews, legal and procurement negotiations, and specific scoping of data domains for initial deployment.
• The company's clinical pipeline includes 10 active programs in Phase I to Phase III trials, of which four are first-in-class molecules.
• ReefIQ's commercial model is designed for multiyear recurring revenue that scales as clients expand their use of the platform across different data domains.

INDUSTRY GLOSSARY

• Agentic AI: AI systems designed to operate autonomously to achieve specific goals, often within a complex ecosystem.
• Bio-native AI: Artificial intelligence models and platforms specifically engineered to process and interpret biological data.
• HYFT Technology: A proprietary, function-aware representation of biology used to identify patterns across sequence and structural biology.
• In silico: Research, experiments, or testing conducted via computer simulation rather than in a living organism or laboratory.
• LensAI: A reasoning and application layer used for target discovery, candidate diligence, and portfolio decision support.
• Multi-omics: A biological analysis approach that integrates multiple data sets, such as genomics, proteomics, and transcriptomics.
• OpenFold3: An open-source model used by discovery teams to predict the structure of biological molecules.
• ReefIQ: A biological data substrate platform that provides context for life sciences by enriching data at ingestion.
• Wet lab: A laboratory where drugs and chemicals are handled in liquid solutions for biological research and testing.

Full Conference Call Transcript

Operator: Hello everyone, thank you for joining us, and welcome to MindWalk Reports Financial Results and recent business highlights for First Quarter Fiscal Year 2027. After today's prepared remarks, we will host a question-and-answer session. I will now hand the call -- the conference over to Dr. Jennifer Bath, President and Chief Executive Officer of MindWalk Holdings Corp. Dr. Bath, please go ahead. Before we begin, I would like to remind listeners that today's discussion contains forward-looking statements.

These statements reflect management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including the company's history of net losses and the ability to convert platform adoptions into contracted recurring arrangements, market acceptance of ReefIQ and LensAI, intellectual property risks, competition, and capital market conditions. A fuller description of these risks appears in the company's annual report, on Form 20-F, and other filings are available on SEDAR+ and EDGAR. All financial figures discussed during this call are Canadian dollars. Financial statements and MD&A are available on the company's website at mindwalkai.com, as well as sec.gov and SEDAR+. A replay of this call will be available following its conclusion today.

I will now turn the call over to Dr. Jennifer Bath, President and Chief Executive Officer of MindWalk Holdings Corp. Please go ahead, Dr. Bath.

Jennifer Bath: Thank you very much. Good afternoon. In this first quarter of fiscal year 2027, MindWalk advanced toward our goal of becoming the leading bio-native AI drug discovery and development company. In June, we launched ReefIQ, our proprietary data platform, and our focus is now on enterprise adoption. For those newer to the MindWalk story, ReefIQ is the substrate layer between complex, unstructured biological data and AI models. It turns that data into structured, biologically meaningful representations, so AI models deliver deeper, more actionable insights for our pharmaceutical partners. ReefIQ's commercial model is built around multi-year recurring revenue relationships that can scale as clients expand their use of the platform.

Because ReefIQ is integrated directly into a client's biological data and the discovery workflows, these relationships are designed to deepen over time. As a trusted partner to many of the world's largest pharmaceutical companies, we know how drug discovery works inside these organizations and what they need from a platform like ReefIQ. Those relationships give us a real advantage as we drive adoption. We have made good progress. We are engaged with multiple large pharmaceutical companies around potential enterprise deployments of ReefIQ. These discussions vary in maturity, and we are encouraged by how the platform is resonating with our clients.

We are not yet in a position to announce specific partners or discuss contract values, but the level of engagement reinforces our conviction of the commercial opportunity. We look forward to providing additional updates as these discussions progressed. These opportunities are substantially larger than our historical LensAI recurring revenue agreements. Investors should not use prior LensAI contracts as a benchmark for the size or the scope of ReefIQ enterprise relationships. We have built a leading wet lab discovery franchise. Our clients include 19 of the top 20 global pharmaceutical companies. And every one of those relationships is a potential opening for ReefIQ.

Two decades of biologics discovery work for our clients across multiple platforms and capabilities has already contributed to several dozen molecules reaching the clinic. 10 are in active Phase I through Phase III trials today, and 4 of those are first-in-class molecules. We are also reshaping how we structure our commercial relationships with our pharmaceutical partners. Increasingly, new engagements are being structured as broader platform partnerships where MindWalk participates in the economics of the assets we help create, rather than simply being paid for discrete projects. This structure aligns our incentives with our partners, has been well received by our clients, and is contributing to increased activity across our commercial funnel.

Today, roughly 80% of our current funnel by value is now structured this way, spanning data management, ReefIQ, and multi-target discovery. We also reached a clear infrastructure milestone with our engineering partner, AMD and Vultr. We validated a production deployment of OpenFold3 on AMD Instinct MI325X GPUs. The first of those results are being published this week. OpenFold3 is open source and any drug discovery team can use it, which is exactly the point. Models commoditize. The layer they run on compounds. Every model run on ReefIQ enriches the biological context for every other program. And LensAI, our reasoning layer, is deliberately model-neutral.

So a client can bring their own model, any open source one, or any third party, and still reason over that same context layer. The compute win simply gives us more room to run discovery and scale ReefIQ. This is a marquee week for that partnership with much more to come. Our internal pipeline continues to advance through preclinical development and we remain excited about the opportunity to drive value in this part of our business. Timelines there are hard to forecast, so we advance multiple programs in parallel and prioritize resources based on the strength of the data.

This quarter, we added experienced leaders to accelerate our IND enabling work and move our best programs toward IND filings and the clinic. We will update the market as they hit scientific, regulatory, and development milestones. Finally, our capital position. This morning we announced a binding commitment for a USD 30 million in unsecured revolving credit facility at a fixed 7% rate drawn as needed. It gives us financial flexibility without issuing equity, which matters given where our stock trades, set against how AI enabled discovery platforms are valued in public and private markets. We do not believe our market capitalization reflects what we have built or the scale of what we are pursuing.

This informs how we think about financing the business and makes this facility particularly attractive to us. This is not a response to a step change in our cash needs. Our model is not capital-intensive. The facility gives us the flexibility to invest behind ReefIQ, advance our internal pipeline, and pursue opportunities as they develop on terms that we believe are very favorable to MindWalk and its shareholders. Our focus is on execution, and we believe sustained delivery will be reflected in the stock over time. Turning to the quarter, revenue grew 21% year over year, and gross margin expanded to 59% from 48%.

The larger loss this quarter reflects deliberate investment behind the commercial opportunity we see ahead of us. Sales and marketing expense increased by $1.9 million. We are investing to build a larger and more durable revenue base, not simply support the business we have today. On the bottom line, this quarter is not directly comparable to the same quarter last year, which included income from discontinued operations. With that, I will turn it over to Scott to take you through the numbers.

Richard Areglado: Thank you, Jennifer, and good afternoon, everyone. I will take you through our first quarter fiscal year 2027 financial results. As a reminder, all figures are in Canadian dollars. Revenue for the first quarter of fiscal year 2027 was $3.8 million versus $3.2 million in the first quarter of fiscal year 2026. This is an improvement of approximately $673,000 or 21%. That represents 5 quarters of consecutive year-over-year revenue growth. Gross margin was $2.2 million, or 59%, for the first quarter of fiscal year 2027, as compared to $1.5 million, or 48%, for the same quarter last year. Looking at operating expenses.

For the quarter ended July 31, 2026, R&D was $1.3 million compared to $1 million in the same period last year. This increase is due primarily to increased salary costs to support the commercial development of our platform. Sales and marketing expenses were $3.2 million for the first quarter of 2027, as compared to $1.3 million in the first quarter of 2026, which included non-recurring costs incurred in the quarter. As I mentioned in our prior call, these are planned investments in our commercial infrastructure and represent increased headcount to support our commercial initiatives, as well as investments in advertising and promotion.

G&A increased to $3.9 million for the quarter ended July 31, 2026, as compared to $3.3 million for the same quarter last year. The increase is due primarily to non-cash stock-based compensation. Net loss and loss from continuing operations was $6.1 million for the first quarter of fiscal year 2027, as compared to net loss from continuing operations of $4.1 million in the first quarter of 2026. Overall net loss in the prior year was $3 million, which included $1.1 million of income from discontinued operations. Turning to the balance sheet. The company ended the quarter with cash balance of $7.6 million as of July 31, 2026.

Net cash used in operating activities was $4 million compared to $4.2 million in the prior year quarter, due in part to non-cash expenses related to share-based payments. Cash was $11.3 million at April 30. I am also pleased with our announcement earlier today of a binding commitment for a USD 30 million senior unsecured revolving credit facility. This facility demonstrates confidence in our long-term strategy around our emerging pipeline and anticipated adoption of ReefIQ and provides the capital necessary to execute on that strategy. With that, I will turn the call back to Jennifer. Jennifer?

Jennifer Bath: Thank you, Scott. As we've mentioned this morning, we announced the binding commitment for USD 30 million of unsecured capital without issuing a single share. And this gives us the runway to execute. The strategy is showing up in the business with revenue up 21% and gross margin at 59%. ReefIQ is a recurring revenue business and it compounds as clients adopt and expand. We are in active negotiations with multiple large pharma companies on ReefIQ enterprise deployments. You will hear from us as those conclude. As mentioned, do not measure them against our historical LensAI agreements. These are a different scale.

On the discovery side, we are moving from discrete projects to platform partnerships where we share in the economics of the assets we help create. Both of these are happening with clients we already have a distribution advantage that no new entrants can buy. On top of that, our internal pipeline adds upside with catalysts ahead. The higher loss this quarter is an investment behind a larger opportunity. The market is moving toward exactly what we built and our job now is to lead it. Operator, we are ready for questions.

Operator: Thank you. We will now begin the question and answer session. [Operator Instructions] And our first question comes from the line of Charles Wallace with H.C. Wainwright.

Charles Wallace: So I guess for my first question, could you maybe help us understand what portion of the $3.8 million in the first quarter revenue was contracted reoccurring platform revenue? And I guess -- yes, I'll start there.

Jennifer Bath: Scott, if you have those numbers before you, I don't know if we do have those broken out. I can say that if we're if by platform recurring revenue, we're referring to ReefIQ. ReefIQ is not a data management program or platform that is currently in place. These are the ones that we've just discussed negotiating, that is like a whole new level of engagement from clients that you'll definitely hear about as we proceed through that. And this was the platform that we just released in June, quite recently. Now, if it's recurring revenue or annual recurring revenue off of the SaaS model subscriptions, we do have that. We have announced that historically.

I'm not sure that we have that broken out since we don't break these out by cost centers, but I can have Scott confirm.

Charles Wallace: Okay, so I guess for my next question. So for the active negotiations that you mentioned with the multiple large pharma partners for the ReefIQ, which as you mentioned, just launched in June, what are the current gating factors in these negotiations? And when do you expect to see these convert in fiscal year 2027?

Jennifer Bath: Fair question. So the gating factors between each group actually differ significantly. In terms of, sorry, we're getting a lot of feedback on our side. In terms of negotiations with clients on our side for gating factors, what we are seeking are primarily people who are already engaged with MindWalk, are running different programs already with MindWalk and primarily starting off with people who are also engaged through the SaaS model subscription. We do look at -- for large pharmaceutical companies, when they're moving into a vendor bringing a vendor into their core infrastructure. None of them are really about whether or not the platform works. They kind of fall in three buckets for us.

The first big one is really about IT security and data governance review, which is something you've probably heard us talk a lot about over the last 6 months. ReefIQ is different in the sense that it sits inside of a client's biological data and its discovery workflows. And so it goes through the same enterprise security, data residency, and governance processes as really any system of record. The second one is legal and procurement. And these are multi-year platform relationships. So instead of like project statements of works that we've done historically with our large pharmaceutical client, and then also when we're sharing in the economics of different assets during co-development and partnership relationships.

So the contract itself is a very new shape. It's very different than the historical contracts we've had. And so it's different for their procurement terms as well. And then I would say, Charles, probably the third component of that is the scoping and just agreeing which programs and which data domains that the first deployment are going to cover, so that it lands cleanly and then it's expanding from there. And so I would say those are kind of the three core areas as companies are by and large taking a relatively new and fairly big step in bringing us fully into the data landscape of what exists throughout their company, oftentimes in a multinational setting.

As far as when we plan to close our first agreement or when we plan to see these start closing. I'm going to leave that question alone for now. I don't want to, I don't want to create that specific of an expectation. But what I am comfortable saying at this point on the call is that we have these negotiations occurring at various different stages, and that includes groups that have worked with us for many years. That also includes one group that's been with us for many years and also has a SaaS model subscription and has been in negotiations, in this particular component across multinational jurisdictions for their company for quite some time.

So we have a very good line of sight on where and how this is going and when we anticipate it closing. But of course, not everything's under our control. So I'll hold off on giving an exact more specific timeline.

Charles Wallace: No, yes, that's very helpful. And then maybe one final question, maybe on the $30 million revolving credit facility. So when do you expect the initial draw from this facility and kind of over what timeframe and how will it be allocated between the ReefIQ commercial rollout and the biological programs -- biologics programs?

Richard Areglado: So we have 60 days to get the credit agreement drawn up. So we won't be able to do anything until the credit agreement is completed. As far as the investments, we'll draw capital as we need it and as we need liquidity, but we still have cash runway in our bank account as well.

Charles Wallace: Great. And maybe one final follow up to that question. Does this credit facility replace kind of the ring-fenced program level financing structure that you have in the Cayman asset in a style of financing?

Richard Areglado: That does not.

Jennifer Bath: Sure, we hear you. Correct, exactly. It absolutely does not replace that. So we still have interested parties that are investing in ring-fenced assets within the Cayman structure and are probably 90%, 95% of the way in terms of completing the legal and the tax planning efforts that go around setting up those structures.

Operator: Your next question comes from the line of Dania Ben-Hail with Jones. Please go ahead.

Danya Ben-Hail: How should investors think about the revenue growth over the next 12 months and next 2 years?

Richard Areglado: Yes, I mean, these initial ReefIQ agreements are probably going to be relatively lumpy. It's just the nature of the structure. They're going to be milestone based, there's engineering efforts at the at the outset, and then they become annual recurring revenue. So I do think revenue is going to be a little lumpy. It's hard to forecast. It really just depends on how quickly we get adoption of ReefIQ.

Danya Ben-Hail: Okay, and so we expect it to be around these numbers during the next few quarters until things settle down and you get more subscriptions and annually and things like that?

Richard Areglado: Yes, I think once we're in a position to announce an agreement, I think we'll take a deeper dive into what the revenue model looks like and what we expect recurring revenue to occur based on the timing of the contract.

Danya Ben-Hail: Yes, OK, thank you. And just another question about the discussions with the pharmaceutical and biotech companies. What are they focused on? Are they getting more engaged with ReefIQ? Is it more the subscriptions right now for the Deep AI? What parts of it are more?

Jennifer Bath: Yes, that's actually a great question, Danya. No, I really appreciate that. So one of the things we've talked about in the past is we definitely went about this from a different direction from others. You will see that there are companies that have a technology and some discovery capabilities that prepared those offerings for others as a partnership model. And really a little bit more on the premise of it's extremely low risk, so we'll backload it, but without really having the proof point or the evidence to support the quality of the work. And that low risk was given in exchange for not having not having that type of a relationship with those clients.

We've really done the exact opposite. We've spent the last 5 years demonstrating our ability to send really good molecules to the clinic that are quite successful in the clinic, and then also demonstrated our ability to do that with an understanding of the function of a molecule and its mechanism of action, providing a greater probability of success in later stages of a clinic. And that's been a really different approach that we've made. So as we enter into these conversations, we've mentioned before, we're working with hundreds of different clients in building these therapeutic drugs.

And one of the biggest changes we've had in the last 2 quarters is that every one of those programs coming in is an integrated lab in the loop with our in silico work intertwined very directly with our wet lab work, providing clients with data sooner, larger amounts of data for more data driven decision making. But there's two components of that really tie in, actually technically three, Danya, that I think specifically address your question. One of them is that all of that data is turned back within LensAI. Clients are directly exposed to the SaaS model subscription. They have the opportunity to use base layer applications within our LensAI.

And that has brought more clients to the table with those inquiries around SaaS model subscriptions. So it expands their ability to work with the data within the platform in which it's being received. The conversations around the partnerships, which are back-loaded but always include some sort of upfront payment, the structure of those being ones that are milestone and royalty based, that is now a conversation happening with every single client.

So that fee for service option that we have provided in the past where we use that opportunity to build a relationship with these clients to be one of their preferred vendors, which is no easy task, and to demonstrate the competencies that we have, I would say superiority that we have in our AI and wet lab drug discovery is what we're building on in those discussions. So every single one of those discussions is now a partnership discussion. There's no longer the opportunity to just walk in the door and put down money for fee for service. So it is a longer negotiation period for us.

So even given the fact that we're still up in revenue with these double digits over last year where we were up significantly in revenue as well, while backloading approximately 80% of the discussions now in the pipeline as partnership discussions to us is bringing us additional confidence. These clients are not walking away from that discussion. They're not -- they're not turning away from it because we've become the trusted provider that we've shown we can execute. And so that's enabled this discussion with going back to your question. Actually, every single one of our clients. And then the third component of that is ReefIQ.

And I would say the majority of the earlier adoption interest and communications we're having from that is from the larger pharmaceutical companies, which I guess makes sense. These are companies that are oftentimes juggling multiple jurisdictions, a lot more siloed data. And are also oftentimes being asked from the top down to find a solution to help their data make sense and to connect their data. And so, we're really seeing it across the board in all three areas. I would say the majority of those conversations, if we had to pick the one that was leading the way, would be partnership discussions, because again, that's not an option to have that discussion with us any longer.

And then the second most would be ReefIQ, where people are looking for an advantage to find meaning in their data, an advantage to get away from hallucination and make their AI models better than their competition. And we're able to bring that to the table with something we've been building for 20 years and something that no one else is able to offer.

Operator: There are no further questions at this time, and this will conclude today's call. Thank you for attending. You may now disconnect.